Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in NAFLD
NCT07881796Completed
- Sponsor
- Shalamar Hospital
- Start
- Apr 2026
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Randomised, single-blind trial of dapagliflozin in non-alcoholic fatty liver disease (NAFLD) (2 arms), sponsored by Shalamar Hospital. Primary endpoint: Body Mass Index at 12 weeks. Started Apr 2026; status: completed.
02
Drugs
dapagliflozin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT07881796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07881796.